stockportfolio.pro
BeOne Medicines AG (ONC)
Healthcare · Biotechnology · NasdaqGS
BeOne Medicines AG revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07M | $238.39M | $198.22M | $428.21M | $308.87M | $1.18B | $1.42B | $2.46B | $3.81B | $5.34B |
| Gross profit | — | $233.41M | $169.51M | $357.02M | $238.22M | $1.01B | $1.13B | $2.08B | $3.22B | $4.67B |
| Net income | $-119.22M | $-93.11M | $-673.77M | $-948.63M | $-1.62B | $-1.46B | $-2.00B | $-881.71M | $-644.79M | $286.93M |
| Net margin | -11141.8% | -39.1% | -339.9% | -221.5% | -526.1% | -123.9% | -141.5% | -35.9% | -16.9% | 5.4% |
Source: BeOne Medicines AG SEC filings (10-K). 12 years of history available in the interactive view.
What growth is priced into ONC stock?
At today's market cap of $27.04B, BeOne Medicines AG is priced for free-cash-flow growth of about 13.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $861.05M from the FY ending 2025-12-31). For comparison, revenue 76.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 12 years of BeOne Medicines AG financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ONC in your portfolio →
BeOne Medicines AG financial history by metric
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
BeOne Medicines AG — frequently asked questions
What is BeOne Medicines AG's revenue?
BeOne Medicines AG (ONC) reported revenue of $5.34B for fiscal year 2025, up 40.2% from the prior year, according to its SEC filings.
Is BeOne Medicines AG profitable?
Yes. ONC earned net income of $286.93M in fiscal 2025, a net margin of 5.4%.
What is ONC's P/E ratio?
BeOne Medicines AG trades at a price-to-earnings ratio of about 58.8 based on the latest data in our nightly-refreshed cache.
How fast is BeOne Medicines AG growing?
ONC's revenue grew at roughly 76.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BeOne Medicines AG have?
As of fiscal year 2025, ONC carried roughly $1.02B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BeOne Medicines AG's gross margin?
ONC's gross margin was 87.5% in fiscal 2025 — gross profit of $4.67B on revenue of $5.34B.
What is BeOne Medicines AG's market cap?
BeOne Medicines AG (ONC) has a market capitalization of about $27.04B, based on the latest data in our nightly-refreshed cache.
When does BeOne Medicines AG's fiscal year end?
ONC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ONC stock?
At today's market cap of $27.04B, BeOne Medicines AG is priced for free-cash-flow growth of about 13.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $861.05M from the FY ending 2025-12-31). For comparison, revenue 76.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from BeOne Medicines AG's official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.